Enanta Pharmaceuticals Statistics
Share Statistics
Enanta Pharmaceuticals has 21.38M
shares outstanding. The number of shares has increased by 0.72%
in one year.
| Shares Outstanding | 21.38M |
| Shares Change (YoY) | 0.72% |
| Shares Change (QoQ) | 0.65% |
| Owned by Institutions (%) | 90.82% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 104 |
| FTD / Avg. Volume | 0.05% |
Short Selling Information
The latest short interest is 2.85M, so 13.35% of the outstanding
shares have been sold short.
| Short Interest | 2.85M |
| Short % of Shares Out | 13.35% |
| Short % of Float | 14.19% |
| Short Ratio (days to cover) | 21.16 |
Valuation Ratios
The PE ratio is -1.89 and the forward
PE ratio is -1.98.
Enanta Pharmaceuticals's PEG ratio is
0.13.
| PE Ratio | -1.89 |
| Forward PE | -1.98 |
| PS Ratio | 3.24 |
| Forward PS | 4.3 |
| PB Ratio | 1.7 |
| P/FCF Ratio | -2.27 |
| PEG Ratio | 0.13 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Enanta Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.21,
with a Debt / Equity ratio of 0.43.
| Current Ratio | 5.21 |
| Quick Ratio | 5.21 |
| Debt / Equity | 0.43 |
| Debt / EBITDA | -0.53 |
| Debt / FCF | -0.57 |
| Interest Coverage | -11.12 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $516,297.71 |
| Profits Per Employee | $-885,839.69 |
| Employee Count | 131 |
| Asset Turnover | 0.18 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -1.74M |
| Effective Tax Rate | 1.48% |
Stock Price Statistics
The stock price has increased by -41.18% in the
last 52 weeks. The beta is 0.77, so Enanta Pharmaceuticals's
price volatility has been higher than the market average.
| Beta | 0.77 |
| 52-Week Price Change | -41.18% |
| 50-Day Moving Average | 5.5 |
| 200-Day Moving Average | 8.03 |
| Relative Strength Index (RSI) | 71.86 |
| Average Volume (20 Days) | 201,498 |
Income Statement
In the last 12 months, Enanta Pharmaceuticals had revenue of 67.64M
and earned -116.05M
in profits. Earnings per share was -5.48.
| Revenue | 67.64M |
| Gross Profit | 67.64M |
| Operating Income | -121.69M |
| Net Income | -116.05M |
| EBITDA | -104.51M |
| EBIT | -106.85M |
| Earnings Per Share (EPS) | -5.48 |
Full Income StatementBalance Sheet
The company has 37.23M in cash and 55.47M in
debt, giving a net cash position of -18.23M.
| Cash & Cash Equivalents | 37.23M |
| Total Debt | 55.47M |
| Net Cash | -18.23M |
| Retained Earnings | -323.04M |
| Total Assets | 322.99M |
| Working Capital | 196.91M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -78.76M
and capital expenditures -17.95M, giving a free cash flow of -96.71M.
| Operating Cash Flow | -78.76M |
| Capital Expenditures | -17.95M |
| Free Cash Flow | -96.71M |
| FCF Per Share | -4.57 |
Full Cash Flow StatementMargins
Gross margin is 100%, with operating and profit margins of -179.92% and -171.58%.
| Gross Margin | 100% |
| Operating Margin | -179.92% |
| Pretax Margin | -174.15% |
| Profit Margin | -171.58% |
| EBITDA Margin | -154.52% |
| EBIT Margin | -179.92% |
| FCF Margin | -142.99% |
